ABL1 (Y253H)
Sign in to save this workspaceABL1 · Variant type: point · HGVS: p.Y253H
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Bosutinib | 100.0% | 0.0% | 87.22 |
| 2 | Ponatinib | 100.0% | 0.0% | 78.23 |
| 3 | Nintedanib | 99.5% | 0.5% | 90.23 |
| 4 | Dasatinib | 99.1% | 0.9% | 87.97 |
| 5 | Vandetanib | 97.4% | 2.6% | 95.74 |
| 6 | Canertinib | 95.5% | 4.5% | 96.49 |
| 7 | Axitinib | 95.1% | 4.9% | 93.23 |
| 8 | Nilotinib | 95.0% | 5.0% | 96.49 |
| 9 | Repotrectinib | 93.9% | 6.1% | 84.21 |
| 10 | Crizotinib | 91.5% | 8.5% | 91.39 |
| 11 | Pacritinib | 90.8% | 9.2% | 88.64 |
| 12 | Brigatinib | 90.6% | 9.4% | 82.96 |
| 13 | Erdafitinib | 87.8% | 12.2% | 95.71 |
| 14 | Dacomitinib | 82.5% | 17.5% | 97.99 |
| 15 | Tivozanib | 81.0% | 19.0% | 92.42 |
| 16 | Erlotinib | 78.0% | 22.0% | 99.75 |
| 17 | Lenvatinib | 73.5% | 26.5% | 97.74 |
| 18 | Sunitinib | 71.2% | 28.8% | 91.73 |
| 19 | Fedratinib | 70.0% | 30.0% | 96.21 |
| 20 | Afatinib | 68.4% | 31.6% | 98.50 |
| 21 | Alectinib | 64.9% | 35.1% | 95.49 |
| 22 | Ripretinib | 62.9% | 37.1% | 92.95 |
| 23 | Entrectinib | 62.4% | 37.6% | 93.69 |
| 24 | Gilteritinib | 55.2% | 44.8% | 88.97 |
| 25 | Avapritinib | 54.2% | 45.8% | 97.73 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Bosutinib | 100.0% | 99.7% | +0.3% |
| Ponatinib | 100.0% | 100.0% | +0.0% |
| Nintedanib | 99.5% | 99.9% | -0.4% |
| Dasatinib | 99.1% | 98.6% | +0.5% |
| Vandetanib | 97.4% | 95.7% | +1.7% |
| Canertinib | 95.5% | 91.6% | +3.9% |
| Axitinib | 95.1% | 99.4% | -4.4% |
| Nilotinib | 95.0% | 98.0% | -3.0% |
| Repotrectinib | 93.9% | 93.6% | +0.3% |
| Crizotinib | 91.5% | 97.0% | -5.5% |
| Pacritinib | 90.8% | 92.0% | -1.2% |
| Brigatinib | 90.6% | 82.8% | +7.8% |
| Erdafitinib | 87.8% | 90.9% | -3.1% |
| Dacomitinib | 82.5% | 80.8% | +1.7% |
| Tivozanib | 81.0% | 95.8% | -14.8% |
| Erlotinib | 78.0% | — | — |
| Lenvatinib | 73.5% | 76.3% | -2.9% |
| Sunitinib | 71.2% | — | — |
| Fedratinib | 70.0% | 82.7% | -12.7% |
| Afatinib | 68.4% | — | — |
| Alectinib | 64.9% | — | — |
| Ripretinib | 62.9% | 82.9% | -20.0% |
| Entrectinib | 62.4% | — | — |
| Gilteritinib | 55.2% | — | — |
| Avapritinib | 54.2% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| haematopoietic_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
| lymphoid_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
| carcinoma_breast | Breast | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.2ms